Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154011
Status:
COMPLETED
Last Update Posted:
2006-09-12
First Post:
2005-09-08
Brief Title:
Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone
Sponsor:
Technische Universität Dresden
Organization:
Technische Universität Dresden
Study Overview
Official Title:
Characterization of Vascular Effects of Rosiglitazone
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to test the hypothesis in healthy subjects that the oral antidiabetic drug rosiglitazone provides additional vascular relaxing or modulating effects in addition to its blood glucose level reducing ability
Detailed Description:
The aim of the study is to investigate the effect of oral rosiglitazone therapy on the vascular responsiveness of different vasoactive compounds angiotensin II insulin histamine and glyceroltrinitrate in healthy subjects Rosiglitazone will be given orally 4 weeks 4mgd titrated to 8 mgd for another 4 weeks as treatment Every subject will receive intravenous stimulation with angiotensin II histamine insulin and glyceroltrinitrate before and after an 8 weeks treatment interval with rosiglitazone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None